| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/21/2013 | CN103255171A Recombinant?virus-like particles of porcine circovirus 2 type codon optimized OFRF2 gene |
| 08/21/2013 | CN103255163A EV71virus-like particles as well as preparation method and application thereof |
| 08/21/2013 | CN103255110A Methods of improving the introduction of DNA into bacterial cells |
| 08/21/2013 | CN103255089A Velogenic Edwardsiella tarda vaccine strain and application thereof |
| 08/21/2013 | CN103254313A Combined CTL antigenic epitope and its application |
| 08/21/2013 | CN103254310A Improved antibody molecules |
| 08/21/2013 | CN103254308A Monoclonal antibody of haemagglutinin protein of H5 subtype of avian influenza virus, or binding activity segment thereof and application of monoclonal antibody or binding activity segment |
| 08/21/2013 | CN103254304A Immune stimulant couplet, preparation method thereof and antineoplastic application of the immune stimulant couplet |
| 08/21/2013 | CN103251960A DNA (deoxyribonucleic acid) vaccine for preventing chronic toxoplasmosis of humans or animals |
| 08/21/2013 | CN103251952A Genetic products differentially expressed in tumors and use thereof |
| 08/21/2013 | CN103251948A Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| 08/21/2013 | CN103251947A Scfv antibodies which pass epithelial and/or endothelial layers |
| 08/21/2013 | CN103251946A Extending time to disease progression or survival in cancer patients using a her dimerization inhibitor |
| 08/21/2013 | CN103251945A Multiple-variable dose regimen for treating tnfalpha-related disorders |
| 08/21/2013 | CN103251944A Preparation method of ursolic acid as immunologic adjuvant vaccine and use |
| 08/21/2013 | CN103251943A Method for preparing type b Haemophilus influenzae and polysaccharide conjugate vaccine |
| 08/21/2013 | CN103251942A Folic-adenovirus tumor targeting compound and preparation method thereof |
| 08/21/2013 | CN103251941A Animal viral vaccine pulsatile release system, and preparation method and application thereof |
| 08/21/2013 | CN103251940A Vaccine |
| 08/21/2013 | CN103251939A Candida albicans attenuated live vaccine as well as preparation method and application thereof |
| 08/21/2013 | CN103251938A Industrial production process of eimeria coccidiosis attenuated vaccine |
| 08/21/2013 | CN103251937A Medicaments and methods for treating headache |
| 08/21/2013 | CN103251931A Application of Cyr61 in psoriasis medicine |
| 08/21/2013 | CN102732486B Porcine circovirus type2 strain and application thereof |
| 08/21/2013 | CN102580087B In-situ adipocyte composite inhibitor for local weight loss and body care of human bodies and preparation method thereof |
| 08/21/2013 | CN102533679B Preparation of virus release buffer solution and application thereof |
| 08/21/2013 | CN102397557B Modification method for gold nanorods and gold nanorods-functional molecule composite |
| 08/21/2013 | CN102154325B Vaccine against human papillomavirus (HPV) as well as preparation method and application thereof |
| 08/21/2013 | CN101978966B Preparation process of H1N1 influenza virus inactivated antibody plasma for treating and producing raw material |
| 08/21/2013 | CN101970670B Methods for inhibiting angiogenesis using egfl8 antagonists |
| 08/21/2013 | CN101932707B Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
| 08/21/2013 | CN101724020B Immunological contraception target universal for mammals and specific antibody thereof |
| 08/21/2013 | CN101616935B Use of monoclonal antibodies specific to the o-acetylated form of gd2 ganglioside for the treatment of certain cancers |
| 08/21/2013 | CN101583629B Modified saccharides |
| 08/21/2013 | CN101573382B Monoclonal antibodies and directed against the human anti-mullerian hormone type ii receptor (amhr-ii) |
| 08/20/2013 | US8513392 Conjugation of streptococcal capsular saccharides |
| 08/20/2013 | US8513391 Monoclonal antibodies for Ebola and Marburg viruses |
| 08/20/2013 | US8513390 Modified antibody compositions, methods of making and using thereof |
| 08/20/2013 | US8513387 Methods and compositions for detecting amyotrophic lateral sclerosis |
| 08/20/2013 | US8513193 Protecting and repairing cartilage and musculoskeletal soft tissues |
| 08/20/2013 | US8513189 Albumin fusion proteins |
| 08/20/2013 | US8513028 Use of MLN51 gene and protein |
| 08/20/2013 | US8513008 signaling cells with an interferon gamma receptor agonists and tumor necrosis factor agonists, then with a second signal comprising a CD40 agonist and natural killer cells, to produce chemokine receptor (CCR7) mature cells, used as immunostimulants |
| 08/20/2013 | US8513006 Tetravalent influenza vaccine and use thereof |
| 08/20/2013 | US8512962 Kit and method for detecting bovine viral diarrhea virus in tissue samples |
| 08/20/2013 | US8512715 Apparatus and method for treating a neuromuscular defect |
| 08/20/2013 | US8512714 Thermoanaerobacter mathranii strain BG1 |
| 08/20/2013 | US8512713 Myxoma virus mutants for cancer treatment |
| 08/20/2013 | US8512712 Reovirus clearance of ras-mediated neoplastic cells from mixed cellular compositions |
| 08/20/2013 | US8512711 VLP based vaccine delivery system |
| 08/20/2013 | US8512710 Class of therapeutic protein based molecules |
| 08/20/2013 | US8512709 Modified amyloid β peptide |
| 08/20/2013 | US8512708 GP96 derived peptides |
| 08/20/2013 | US8512707 Methods of treating drug-resistant cancers |
| 08/20/2013 | US8512706 Compositions of F(ab′)2 antibody fragments |
| 08/20/2013 | US8512705 Engineered anti-TSLP antibody |
| 08/20/2013 | US8512704 Tmem27 antibody |
| 08/20/2013 | US8512703 Idiotypic vaccine |
| 08/20/2013 | US8512701 Anti-CXCL13 and anti-CXCR5 antibodies for the prevention and treatment of cancer and cancer cell migration |
| 08/20/2013 | US8512700 Antibody protective agent and methods of using same |
| 08/20/2013 | US8512699 Anti-VEGF antibodies |
| 08/20/2013 | US8512698 Compositions and methods for diagnosing and treating an inflammation |
| 08/20/2013 | CA2699410C Attenuated mycoplasma gallisepticum strains |
| 08/20/2013 | CA2669800C Nerve elongation promoter and elongation inhibitor |
| 08/20/2013 | CA2641310C Igf-ir antagonists as adjuvants for treatment of prostate cancer |
| 08/20/2013 | CA2628397C Changing th1/th2 balance in split influenza vaccines with adjuvants |
| 08/20/2013 | CA2508660C Antibodies against pd-1 and uses therefor |
| 08/20/2013 | CA2492333C Canine respiratory coronavirus (crcv) spike protein, polymerase and hemagglutinin/esterase |
| 08/20/2013 | CA2477794C System and method for the production of recombinant glycosylated proteins in a prokaryotic host |
| 08/20/2013 | CA2445349C Anti-cd40 monoclonal antibody |
| 08/20/2013 | CA2407301C Hsp60 sequence from piscirickettsia salmonis |
| 08/15/2013 | WO2013120066A1 Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
| 08/15/2013 | WO2013119960A2 Novel modulators and methods of use |
| 08/15/2013 | WO2013119957A1 Weight reduction through inactivation of gastric orexigenic mediator producing cells |
| 08/15/2013 | WO2013119863A1 Timothy grass allergens and methods and uses for immune response modulation |
| 08/15/2013 | WO2013119853A1 Epitopes from allergen proteins and methods and uses for immune response modulation |
| 08/15/2013 | WO2013119800A1 Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness |
| 08/15/2013 | WO2013119716A1 Compositions and methods for using csf1r inhibitors |
| 08/15/2013 | WO2013119715A1 Determination of immunogenic peptides in lysosomal enzymes and induction of oral tolerance |
| 08/15/2013 | WO2013119714A1 Cd47 antibodies and methods of use thereof |
| 08/15/2013 | WO2013119693A1 Emp2 regulates angiogenesis in cancer cells through induction of vegf |
| 08/15/2013 | WO2013119683A1 Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses |
| 08/15/2013 | WO2013119202A1 Cancer treatment and monitoring methods using ox40 agonists |
| 08/15/2013 | WO2013118033A1 NOVEL BINDING SITE OF ΙΚΚ-β |
| 08/15/2013 | WO2013117912A1 Sheep nematode vaccine |
| 08/15/2013 | WO2013117705A1 Targeting of chondroitin sulfate glycans |
| 08/15/2013 | WO2013117647A1 Mica binding agents |
| 08/15/2013 | WO2013117519A1 Method of preventing allergies |
| 08/15/2013 | WO2013116965A1 Combined antigen and dna vaccine for preventing and treating rsv infection |
| 08/15/2013 | WO2013093524A3 Method for preparing amorphous precipitated protein particles |
| 08/15/2013 | WO2013084148A3 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3 |
| 08/15/2013 | WO2013082317A3 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof |
| 08/15/2013 | WO2013074816A3 Novel inhibitors of nox1 |
| 08/15/2013 | WO2013030670A3 Tissue targeted fusobacterium antigenic activation of the immune response to treat intestinal cancers |
| 08/15/2013 | WO2013006055A8 A process for detergent-free production of outer membrane vesicles of a gram-negative bacterium |
| 08/15/2013 | WO2012170969A3 Pro-coagulant compounds and methods of use thereof |
| 08/15/2013 | WO2012156975A9 COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| 08/15/2013 | WO2012094386A9 Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus |
| 08/15/2013 | WO2011140249A3 Antibodies that bind csf1r |
| 08/15/2013 | US20130210673 Polypeptide Display Libraries and Methods of Making and Using Thereof |